Kairos Pharma Ltd
KAPA0.930USD
+0.063+7.22%
Market hours （ET）Quotes delayed by 15 min
16.50MMarket Cap
LossP/E TTM
More Details of Kairos Pharma Ltd Company
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its products consist of five pre-clinical or clinical-trial stage drug candidates developed by it and designed to target immune response, and two therapeutic agents developed by its Enviro Therapeutics, Inc. (Enviro) subsidiary and designed to increase anti-tumor response in conjunction with cancer therapies by addressing resistance to these agents. Its product portfolio includes a variety of technologies licensed by its Enviro subsidiary and consists of compositions and methods for treating diseases and conditions by targeting CD105 and depleting mitochondrial DNA from the circulation. Its products include KROS 101, 102, 201, 301, 401, ENV 105 and 205.
Kairos Pharma Ltd Info
Ticker SymbolKAPA
Company nameKairos Pharma Ltd
IPO dateSep 16, 2024
CEODr. John S. Yu, M.D.
Number of employees1
Security typeOrdinary Share
Fiscal year-endSep 16
Address2355 Westwood Blvd. #139
CityLOS ANGELES
Stock exchangeNYSE American Consolidated
CountryUnited States of America
Postal code90064
Phone18184045541
Websitehttps://kairospharma.com
Ticker SymbolKAPA
IPO dateSep 16, 2024
CEODr. John S. Yu, M.D.
Company Executives of Kairos Pharma Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. John S. Yu, M.D.
Dr. John S. Yu, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
5.34M
--
Dr. Rahul Singhvi
Dr. Rahul Singhvi
Independent Director
Independent Director
30.12K
--
Mr. Douglas W. (Doug) Samuelson, CPA
Mr. Douglas W. (Doug) Samuelson, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Neil Bhowmick, Ph.D.
Dr. Neil Bhowmick, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Ramachandran Murali, Ph.D.
Dr. Ramachandran Murali, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Hyun W. Bae, M.D.
Dr. Hyun W. Bae, M.D.
Independent Director
Independent Director
--
--
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. John S. Yu, M.D.
Dr. John S. Yu, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
5.34M
--
Dr. Rahul Singhvi
Dr. Rahul Singhvi
Independent Director
Independent Director
30.12K
--
Mr. Douglas W. (Doug) Samuelson, CPA
Mr. Douglas W. (Doug) Samuelson, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Neil Bhowmick, Ph.D.
Dr. Neil Bhowmick, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Ramachandran Murali, Ph.D.
Dr. Ramachandran Murali, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Hyun W. Bae, M.D.
Dr. Hyun W. Bae, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 23
Updated: Sat, Aug 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Yu (John S)
25.75%
Technomedics Management and Systems, Inc
5.66%
Bhowmick (Neil Ph.D.)
5.45%
Murali (Ramachandran Ph.D.)
0.66%
Samuelson (Doug)
0.51%
Other
61.98%
Shareholders
Shareholders
Proportion
Yu (John S)
25.75%
Technomedics Management and Systems, Inc
5.66%
Bhowmick (Neil Ph.D.)
5.45%
Murali (Ramachandran Ph.D.)
0.66%
Samuelson (Doug)
0.51%
Other
61.98%
Shareholder Types
Shareholders
Proportion
Individual Investor
32.72%
Corporation
5.66%
Investment Advisor
0.86%
Venture Capital
0.30%
Investment Advisor/Hedge Fund
0.11%
Hedge Fund
0.08%
Research Firm
0.03%
Other
60.24%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
17
286.70K
1.38%
-1.69M
2025Q2
19
9.54M
54.94%
+1.17M
2025Q1
19
10.48M
74.82%
+2.27M
2024Q4
13
9.19M
70.90%
+3.62M
2024Q3
9
8.91M
68.86%
+8.91M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Yu (John S)
5.34M
25.75%
--
--
Jul 28, 2025
Technomedics Management and Systems, Inc
1.17M
5.66%
--
--
Jul 28, 2025
Bhowmick (Neil Ph.D.)
1.13M
5.45%
--
--
Jul 28, 2025
Murali (Ramachandran Ph.D.)
137.52K
0.66%
--
--
Jul 28, 2025
Samuelson (Doug)
104.89K
0.51%
--
--
Jul 28, 2025
The Vanguard Group, Inc.
10.72K
0.05%
--
--
Aug 31, 2025
XTX Markets LLC
62.75K
0.3%
+62.75K
--
Jun 30, 2025
Bae (Hyun W. M.D.)
44.29K
0.21%
--
--
Jul 28, 2025
SevenBridge Financial Group, LLC
44.29K
0.21%
--
--
Jun 30, 2025
Aptus Capital Advisors, LLC
44.29K
0.21%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
